Merit Medical Systems, Inc. (NASDAQ:MMSI) Holdings Boosted by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund raised its stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 1.3% in the fourth quarter, HoldingsChannel.com reports. The fund owned 30,342 shares of the medical instruments supplier’s stock after buying an additional 400 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Merit Medical Systems were worth $2,935,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in MMSI. Farther Finance Advisors LLC boosted its position in Merit Medical Systems by 32.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,056 shares of the medical instruments supplier’s stock valued at $104,000 after purchasing an additional 260 shares during the period. Harvest Fund Management Co. Ltd bought a new stake in Merit Medical Systems in the third quarter valued at $120,000. GAMMA Investing LLC boosted its holdings in shares of Merit Medical Systems by 14.7% during the fourth quarter. GAMMA Investing LLC now owns 1,494 shares of the medical instruments supplier’s stock valued at $144,000 after acquiring an additional 191 shares during the period. TD Private Client Wealth LLC grew its position in shares of Merit Medical Systems by 13.9% during the third quarter. TD Private Client Wealth LLC now owns 1,732 shares of the medical instruments supplier’s stock worth $171,000 after acquiring an additional 211 shares during the last quarter. Finally, Ballentine Partners LLC bought a new position in shares of Merit Medical Systems during the fourth quarter worth about $200,000. 99.66% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

MMSI has been the subject of a number of analyst reports. StockNews.com lowered shares of Merit Medical Systems from a “buy” rating to a “hold” rating in a research note on Sunday, November 3rd. Canaccord Genuity Group dropped their price target on shares of Merit Medical Systems from $128.00 to $127.00 and set a “buy” rating on the stock in a research report on Wednesday. Barrington Research decreased their price objective on shares of Merit Medical Systems from $115.00 to $111.00 and set an “outperform” rating for the company in a report on Wednesday. Wells Fargo & Company lowered their price objective on shares of Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, Piper Sandler restated an “overweight” rating and issued a $116.00 target price (up from $114.00) on shares of Merit Medical Systems in a research report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $108.40.

Merit Medical Systems Price Performance

NASDAQ MMSI opened at $98.52 on Friday. Merit Medical Systems, Inc. has a 1 year low of $70.70 and a 1 year high of $111.45. The business’s fifty day moving average is $102.83 and its two-hundred day moving average is $99.88. The stock has a market capitalization of $5.74 billion, a P/E ratio of 48.29, a P/E/G ratio of 2.34 and a beta of 0.87. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.